Metraipolis › archive › dc_8ca5cff7095e

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial — Europe PMC PMID:41621431

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41621431
DOI
10.1016/s2213-8587(25)00319-5
License (as archived)
solo-consultazione
Archived
2026-11-06T11:14:02.542Z
SHA-256 of the archived text
b11e6235ce7f898a0b55ea8b073899e8eb7def49b9427dc1e7e753989abdee21
Stable URL of this page
https://metraipolis.com/documento/dc_8ca5cff7095e

How to cite

3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial — Europe PMC PMID:41621431 — Europe PMC (en), https://europepmc.org/article/MED/41621431 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8ca5cff7095e (Metraipolis archive dc_8ca5cff7095e, sha256 b11e6235ce7f898a0b55ea8b073899e8eb7def49b9427dc1e7e753989abdee21)
BibTeX
@misc{dc8ca5cff7095e,
  title = {3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial — Europe PMC PMID:41621431},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41621431},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8ca5cff7095e; sha256 b11e6235ce7f898a0b55ea8b073899e8eb7def49b9427dc1e7e753989abdee21},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41621431. Agents can read the archived copy with the MCP tool read_document.